Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-0390, an Investigational Emopamil-binding Protein (EBP) Inhibitor for the Treatment of Brain Cancer
- Monday, July 18, 2022, 7:15
- Environment
- Add a comment
CAMBRIDGE, Mass., July 18, 2022 /PRNewswire/ — Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for DSP-0390, an investigational emopamil-binding…
About the Author
adminasapcorp has written 41562 stories on this site.